Belgium· BE-AMP-SAM505262-00
Ninlaro 2.3 mg
A ixazomib product containing ixazomib citrate, registered in Belgium by Takeda Pharma. The same ATC class is registered in 13 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Ixazomib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01XG03 (ixazomib), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Ixazomib · ATC L01XG03
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ixazomib costs, country by country.
Normalised to the WHO defined daily dose (0.43 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ixazomib · price per daily dose (0.43 mg)
USD · FX 28 Sept 2026
- CH Switzerland$395.98
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Ixazomib Citrate
- Manufacturer
- Takeda Pharma
- Country
- Belgium (BE)
- ATC code
- L01XG03
- ATC class
- Ixazomib
- Defined daily dose
- 0.43 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 2
- be_apb7720584
- be_apb3652013
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
226 interactions on record for ixazomib.
Graded by severity as the source publishes them — 45 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ixazomib · interactions on record
226 records
- 45 severe
- 181 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- RifampicinJ04AB02severe
- RifabutinJ04AB04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ixazomib in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United KingdomIxazomib 2.3mg capsulesTakeda UK Ltd
- United StatesNINLAROTakeda Pharmaceuticals America, Inc.
- CzechiaNINLAROTakeda Pharma A/S, Vallensbaek Strand
- SpainNINLARO 2,3 MG CAPSULAS DURASTakeda Pharma A/S
- FinlandNINLAROTakeda Pharma A/S
- FranceNINLARO 2,3 mg, géluleTAKEDA PHARMA (DANEMARK)
- CanadaNINLAROTAKEDA CANADA INC
- IcelandNinlaroTakeda Pharma A/S
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ninlaro
- Liechtenstein · Ninlaro
- Norway · Ninlaro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f35075a9-5d4d-4dcc-b4ea-b3ed836380b0 GET /v1/drugs/f35075a9-5d4d-4dcc-b4ea-b3ed836380b0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Capsule, hard",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Ninlaro 2.3 mg",
"name_fr": "Ninlaro 2.3 mg",
"name_nl": "Ninlaro 2.3 mg",
"amp_code": "SAM505262-00",
"strengths": [
"3.3000",
"2.3000"
],
"pack_count": 1,
"substances": [
"Ixazomib Citrate",
"Ixazomib",
"Potassium Hydroxide",
"Propylene Glycol"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Ixazomib",
"authorisation_numbers": [
"EU/1/16/1094/001"
]
}See everything about ixazomib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.